Jan 30
Registration statement
S-3
Registration statement
DRMA · Dermata Therapeutics, Inc. · Documents
$0.76
+0.00 (+0.28%)
At close · Nov 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because of historical and expected operating losses and net operating cash flow deficits, there is substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the financial statements, which is not alleviated by management's plans.”View the 10-Q filed Aug 11, 2026
Market Cap
$3.07M
Shares
4.02M
Volume · Nov 6
60.22K
Avg daily vol (3M)
3.39M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2025
Jan 23
Current report
8-K
Events of Jan 21
Entered into a material agreement, Unregistered sale of equity, Other events
Jan 21
Current report
8-K
Events of Jan 17
Entered into a material agreement, Regulation FD disclosure
2024
Nov 14
Current report
8-K
Events of Nov 13
Financial results, Regulation FD disclosure
Nov 13
Sep 19
Registration statement
S-3
Registration statement
Sep 17
Current report
8-K
Events of Sep 16
Entered into a material agreement, Unregistered sale of equity, Other events
Aug 7
Current report
8-K
Financial results, Regulation FD disclosure
Aug 7
Aug 2
Current report
8-K
Other events
Jul 3
Registration statement
S-3
Registration statement
Jun 7
Current report
8-K
Entered into a material agreement
Jun 5
Current report
8-K
Events of Jun 4
Other events
May 24
Current report
8-K
Events of May 20
Delisting notice or listing transfer
May 17
May 15
Current report
8-K
Events of May 14
Delisting notice or listing transfer, Other events
May 15
Current report
8-K
Financial results, Regulation FD disclosure
May 15
May 14
May 7
Current report
8-K
Director or officer change, or executive pay, Shareholder vote results
Mar 26
Proxy statement
DEF 14A
Proxy statement
Mar 26
Annual report to holders
ARS
Annual report to holders
Mar 26
Proxy statement
DEFA14A
Proxy statement
Mar 21
Current report
8-K
Financial results, Regulation FD disclosure
Mar 21
Mar 4
Proxy statement
PRE 14A
Proxy statement
Jan 12
Current report
8-K
Shareholder vote results
2023
Dec 8
Proxy statement
DEF 14A
Proxy statement
Dec 7
Registration statement
S-3
Registration statement
Nov 29
Proxy statement
PRE 14A
Proxy statement
Nov 17
Current report
8-K
Events of Nov 16
Entered into a material agreement, Unregistered sale of equity, Change to shareholders' rights
Nov 16
Current report
8-K
Events of Nov 15
Delisting notice or listing transfer
Nov 9
Current report
8-K
Financial results, Change of auditor, Regulation FD disclosure
Nov 9
Aug 10
Current report
8-K
Financial results, Regulation FD disclosure
Aug 10
Aug 3
Current report
8-K
Events of Jul 28
Change of auditor, Director or officer change, or executive pay, Shareholder vote results
Jul 12
Proxy statement
DEFA14A
Proxy statement
Jul 7
Registration statement
S-1
Registration statement
Jun 23
Proxy statement
DEF 14A
Meeting Aug 3, 2023
Proxy statement
Jun 23
Annual report to holders
ARS
Annual report to holders
Jun 23
Proxy statement
DEFA14A
Proxy statement
May 24
Current report
8-K
Events of May 23
Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure
May 11
Current report
8-K
Financial results, Regulation FD disclosure
May 11
Mar 28
Annual report
10-K/A
Ended Dec 31
Annual report for the period ended Dec 31, 2022
Mar 28
Current report
8-K
Other events
Mar 20
Current report
8-K
Events of Mar 16
Entered into a material agreement, Regulation FD disclosure
Mar 16
Registration statement
S-1/A
Registration statement
Mar 15
Registration statement
S-1/A
Registration statement
Showing 51–100 of 145 documents